Announced Sat, 4 Apr · 15:19 IST
Granules India's US arm completes USFDA cGMP audit at Chantilly with 4 observations
Business Updates View source PDF
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.6%1-day move
₹610.10
prior close
₹605.55
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.4+2.0+1.6+2.8+4.6+5.6+4.0+3.6+3.7+6.6+15.2+20.6+25.9+39.5
Up moveDown movePending
AI summary
Granules India announced that its US subsidiary Granules Pharmaceuticals Inc (GPI) completed a routine USFDA cGMP audit at its Chantilly, Virginia facility conducted from March 30 to April 3, 2026. The inspection, the second at Chantilly in a year, ended with 4 Form 483 observations. The company clarified these are procedural matters with no data integrity issues flagged, and stated it will address the observations within stipulated timelines.
Likely market impact
Mildly positive — audit completed without data integrity concerns, but 4 observations may draw regulatory scrutiny. Investors should watch for timely resolution.